NSE · DRREDDY
Dr Reddys Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹5,137 Cr with net profit ₹405 Cr — a 7.88% net margin, versus 11.97% the period before.
Shareholding
As of 2026-06-30
- Promoter26.64%
- Public9.55%
- FII32.07%
- DII31.74%
4,46,086 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.29× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #7 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,76,076 Cr | 38.31 | 5.7 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,989 Cr | 216.2 | 3.48 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,359 Cr | 20.68 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,12,356 Cr | 70.55 | 5 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,548 Cr | 193.76 | 6.59 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,278 Cr | 344.7 | 18.15 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd.(this company) | ₹95,503 Cr | 431.77 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,440 Cr | 100.35 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,902 Cr | 545.89 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,674 Cr | 286.29 | 4.9 | 16.66% | 15.65% |
AI analysis
AI-generated · google/gemini-2.5-flashDr Reddys Laboratories Ltd., symbol DRREDDY, has a market capitalization of Rs 102089 Cr. The company reported a revenue of Rs 33741.2 Cr with a profit margin of 12.49%. Annual revenue growth stood at 16.5%.
Positives
- +Revenue grew by 16.5% to Rs 33741.2 Cr.
- +Debt-to-equity ratio is low at 0.17.
- +Promoter pledge is 0%, indicating no shares are pledged.
- +The dividend yield is 65%.
Negatives
- −The trailing twelve-month PE ratio is high at 461.55.
- −Net profit significantly declined from Rs 1209.9 Cr in Dec 2025 to Rs 220.9 Cr in Mar 2026.
- −EBITDA decreased from Rs 1635.3 Cr in Dec 2025 to Rs 300.8 Cr in Mar 2026.
- −Promoter holding has decreased from a historical high of 26.6344% in March 2026 compared to earlier periods where data is available, for instance March 2018 where it was not specified but pledge was 0.72%.
Financial performance
Dr Reddys Laboratories Ltd. recorded a revenue of Rs 33741.2 Cr, indicating a revenue growth of 16.5%. The annual net profit for March 2026 was Rs 4196 Cr. Quarterly revenue for December 2025 was Rs 8753.4 Cr, with a net profit of Rs 1209.9 Cr. Meanwhile, for March 2026, quarterly revenue was Rs 7546.4 Cr and net profit was Rs 220.9 Cr.
Profitability & returns
The company's profit margin is 12.49%. Return on equity (ROE) was 11.07% and return on capital employed (ROCE) was 12.54%. Earnings per share (EPS) for the year was Rs 48.01. The dividend yield is 65%.
Balance sheet
Dr Reddys Laboratories Ltd. has a debt-to-equity ratio of 0.17, indicating a relatively low level of debt. The book value per share stands at Rs 456.14.
Ownership & pledges
As of March 31, 2026, promoter shareholding was 26.63%. Foreign Institutional Investors (FIIs) held 33.08% and Domestic Institutional Investors (DIIs) held 30.72%. Public shareholding was 9.57%. Total institutional holding was 63.80%. There were no promoter shares pledged, as indicated by a 0% promoter pledge.
Data as of — price: 2026-07-29 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Dr Reddys Laboratories Ltd.share price & fundamentals